Want to join the conversation?
$ALXN's research and development expenses for 2015 rose by 38% from 2014. The increase was primarily related to rise in clinical expenses on expansion of studies for eculizumab, ALXN 1007, ALXN 1210, and other programs, licensing agreement expenses, discovery research, payroll and benefit expenses as well as facilities and other costs.
$AAL is giving pay hikes to its employees but investors are sulking.
$APC stock tumbled more than 5.6% after last week's fatal home explosion in Firestone, Colorado prompted the company to close more than 3,000 wells for weeks.
Unicorn Frappuccino. The latest hit from $SBUX. Can't wait to see how this will affect its results.
At what point should $AMZN consider a stock split? $1000 per share seems pretty high.